Sideroblastic Anemia Medical Services in China

Sideroblastic anemia (SA) is a heterogeneous group of rare hematologic disorders characterized by defective heme synthesis in erythroblasts, leading to the accumulation of non-heme iron in mitochondrial granules—visible as ringed sideroblasts on Prussian blue-stained bone marrow aspirates. This impairment results in ineffective erythropoiesis, microcytic or normocytic anemia, systemic iron overload, and variable clinical severity. SA is broadly classified into hereditary (congenital) and acquired forms. Hereditary SA most commonly arises from mutations in genes involved in mitochondrial iron-sulfur cluster biogenesis or heme synthesis—such as *ALAS2*, *SLC25A38*, *GLRX5*, *ABCB7*, and *FXN* (in Friedreich ataxia–associated cases). Acquired SA is frequently linked to myelodysplastic syndromes (MDS), particularly refractory anemia with ring sideroblasts (RARS) and MDS–RS–SF (with *SF3B1* mutation), but may also result from chronic alcohol use, copper deficiency, zinc toxicity (e.g., from denture adhesives), certain medications (e.g., isoniazid, chloramphenicol, linezolid), or mitochondrial toxins. Epidemiologically, SA is exceedingly rare: hereditary forms affect fewer than 1 in 1,000,000 individuals globally, while acquired SA accounts for ~5–10% of all MDS cases—translating to an estimated incidence of 0.5–2 per 100,000 adults annually in developed countries. It predominantly affects older adults (median age >70 years) in acquired forms, whereas X-linked *ALAS2*-related SA typically presents in childhood or early adulthood, often with male predominance. Key risk factors include germline genetic predisposition, aging, clonal hematopoiesis, chronic alcoholism, prolonged exposure to mitochondrial toxins, and nutritional deficiencies (copper, vitamin B6). Patients commonly experience fatigue, pallor, dyspnea on exertion, tachycardia, and signs of iron overload—including hepatomegaly, skin hyperpigmentation, diabetes mellitus, and cardiac arrhythmias—especially after repeated transfusions. Quality of life is significantly impaired due to chronic anemia-related debility, transfusion dependency, chelation therapy side effects (e.g., gastrointestinal upset, auditory/ocular toxicity), and psychological burden associated with lifelong monitoring and uncertainty about disease progression. In hereditary forms, some patients respond well to high-dose pyridoxine (vitamin B6), improving hemoglobin and reducing transfusion needs; however, many develop progressive iron overload requiring phlebotomy or chelation. Acquired SA, especially MDS-associated, carries higher risks of leukemic transformation and reduced overall survival. Multidisciplinary management—including hematologic surveillance, iron quantification (serum ferritin, MRI liver iron concentration), cardiac evaluation, and genetic counseling—is essential. Early diagnosis via bone marrow examination with iron staining and molecular testing enables tailored intervention and improves long-term outcomes.

Sideroblastic anemia (SA) is a heterogeneous group of disorders characterized by defective heme synthesis in erythroblasts, resulting in the pathognomonic accumulation of non-heme iron within mitochondrial matrices—visualized as ringed sideroblasts on Prussian blue-stained bone marrow aspirates. The underlying defect impairs incorporation of iron into protoporphyrin IX to form heme, leading to mitochondrial iron overload, ineffective erythropoiesis, and systemic iron accumulation. Causes are broadly classified as hereditary (congenital) or acquired, with overlapping pathophysiological mechanisms centered on mitochondrial metabolism, iron-sulfur cluster biogenesis, heme biosynthesis, and mitochondrial protein translation.

Hereditary SA arises predominantly from germline mutations affecting genes critical for mitochondrial function. X-linked sideroblastic anemia (XLSA), the most common inherited form, results from loss-of-function mutations in *ALAS2*, encoding the erythroid-specific 5-aminolevulinate synthase—the rate-limiting enzyme in heme biosynthesis. Autosomal recessive forms include mutations in *SLC25A38*, essential for glycine import into mitochondria (a substrate for ALAS2), and *ABCB7*, involved in iron-sulfur cluster export; its deficiency causes X-linked sideroblastic anemia with ataxia (XLSA/A). Other genetic causes involve *GLRX5* (glutaredoxin-5, required for iron-sulfur cluster assembly), *PPOX* (protoporphyrinogen oxidase), *FECH* (ferrochelatase), and mitochondrial DNA mutations (e.g., *MT-ATP6*, *MT-RNR1*), often presenting with multisystem involvement including myopathy, neuropathy, or diabetes.

Acquired SA is more prevalent in clinical practice and frequently associated with clonal hematopoiesis. Myelodysplastic syndrome–associated SA (MDS-SA), particularly refractory anemia with ring sideroblasts (RARS) and MDS–RS with multilineage dysplasia, accounts for the majority of adult cases. These are commonly driven by somatic mutations in *SF3B1*, a spliceosome component; >80% of RARS cases harbor *SF3B1* mutations, correlating with favorable prognosis and ring sideroblast burden. Other clonal causes include chronic myelomonocytic leukemia (CMML) and therapy-related myeloid neoplasms.

Non-clonal acquired SA may be triggered by reversible metabolic or toxic insults. Alcohol abuse is a well-established trigger, inducing mitochondrial dysfunction and impairing ALAS2 activity and pyridoxal phosphate (vitamin B6) cofactor availability. Copper deficiency—often secondary to excessive zinc supplementation, gastric bypass surgery, or malabsorption—disrupts cytochrome c oxidase and ferroxidase activity, impairing iron mobilization and heme synthesis. Certain medications act as direct mitochondrial toxins: isoniazid (inhibits pyridoxal kinase, depleting active B6), chloramphenicol (inhibits mitochondrial protein synthesis), linezolid (binds 23S rRNA), and busulfan (induces oxidative mitochondrial damage). Lead poisoning inhibits δ-aminolevulinic acid dehydratase (ALAD) and ferrochelatase, causing functional heme deficiency and secondary sideroblast formation.

Risk factors include advanced age (peak incidence >60 years for acquired SA), male sex (for XLSA due to X-linked inheritance), chronic alcohol use (>3 drinks/day over ≥5 years), prolonged exposure to heavy metals (e.g., lead in occupational settings), history of hematologic malignancy or cytotoxic chemotherapy, bariatric surgery (predisposing to copper/zinc imbalance), and nutritional deficiencies (e.g., severe B6, copper, or folate deficiency). Genetic predisposition is significant: family history of early-onset anemia, unexplained neurologic symptoms, or consanguinity increases suspicion for autosomal recessive forms. Environmental exposures such as industrial solvents (e.g., benzene derivatives) and pesticides may contribute via oxidative stress-mediated mitochondrial injury, though evidence remains associative. Importantly, idiopathic SA—without identifiable genetic, clonal, or toxic etiology—represents a diagnosis of exclusion after comprehensive evaluation including next-generation sequencing of bone marrow, serum copper/zinc levels, urinary lead, and hepatic iron quantification. Accurate classification guides management: pyridoxine responsiveness is seen in ~30% of *ALAS2*-mutated cases and some *PPOX*/*FECH* defects; whereas *SF3B1*-mutated MDS-SA may respond to luspatercept, and copper repletion corrects deficiency-induced SA. Failure to identify modifiable triggers risks progression to transfusion dependence, secondary hemochromatosis, and increased risk of leukemic transformation in clonal disease.

Sideroblastic anemia (SA) is a heterogeneous group of disorders characterized by defective heme synthesis in erythroblasts, resulting in the accumulation of non-heme iron within mitochondrial matrices—visualized as ringed sideroblasts on Prussian blue-stained bone marrow aspirates. SA may be inherited (e.g., X-linked sideroblastic anemia due to mutations in *ALAS2*, autosomal recessive forms involving *SLC25A38*, *GLRX5*, or *ABCB7*) or acquired (e.g., clonal myeloid neoplasms such as myelodysplastic syndrome with ring sideroblasts [MDS-RS], or reversible forms secondary to alcohol abuse, copper deficiency, zinc toxicity, or certain medications including isoniazid and chloramphenicol). Clinical presentation varies widely depending on etiology, severity of anemia, rate of progression, and coexisting comorbidities.

Early symptoms are often insidious and nonspecific, reflecting chronic, progressive anemia. Patients commonly report fatigue, diminished exercise tolerance, and mild exertional dyspnea—typically developing over weeks to months. Pallor, particularly of the conjunctivae and nail beds, may be subtle initially but becomes more apparent with worsening hemoglobin levels. Mild tachycardia at rest or with minimal activity may be noted on physical examination before overt cardiac signs emerge. Some individuals experience lightheadedness or intermittent headache, especially upon orthostatic change, attributable to reduced cerebral oxygen delivery. In pediatric-onset inherited forms, early manifestations may include failure to thrive, developmental delay, or recurrent infections—particularly when associated with mitochondrial dysfunction or multisystem involvement (e.g., *PUS1* or *YARS2* mutations).

Typical symptoms reflect moderate-to-severe anemia and iron overload. Hemoglobin levels frequently range from 7–10 g/dL in chronic cases; transfusion-dependent patients may present with profound anemia (Hb < 6 g/dL), manifesting as marked weakness, profound dyspnea at rest, palpitations, and angina pectoris in those with underlying coronary artery disease. Physical findings include pallor, koilonychia (spoon-shaped nails), glossitis, and occasionally mild splenomegaly—especially in refractory or clonal forms. A hallmark feature is systemic iron overload, even in non-transfused patients, due to ineffective erythropoiesis-driven upregulation of hepcidin suppression and consequent increased intestinal iron absorption. This leads to elevated serum ferritin (>1000 ng/mL), increased transferrin saturation (>80%), and eventual deposition in parenchymal organs. Hepatomegaly, abnormal liver enzymes (elevated ALT/AST), and glucose intolerance may signal early hepatic iron loading. Cardiac iron deposition can cause arrhythmias (e.g., atrial fibrillation), diastolic dysfunction, or, in advanced cases, restrictive cardiomyopathy and heart failure.

Accompanying symptoms depend on the underlying cause. In MDS-RS, patients may exhibit cytopenias beyond anemia—including neutropenia (increased risk of bacterial infections) and thrombocytopenia (easy bruising, mucocutaneous bleeding). Neurological symptoms such as peripheral neuropathy, ataxia, or optic atrophy occur in mitochondrial-associated SA (e.g., *MT-ATP6*, *MT-TL1* mutations) or syndromic forms like Pearson marrow-pancreas syndrome. Alcohol-related SA may present with concurrent signs of chronic liver disease (e.g., spider angiomas, ascites) or Wernicke-Korsakoff features. Copper deficiency—often iatrogenic (e.g., after bariatric surgery or excessive zinc supplementation)—may produce myeloneuropathy mimicking subacute combined degeneration, with sensory ataxia and spastic paraparesis. Drug-induced SA typically resolves upon discontinuation but may be accompanied by drug-specific toxicities (e.g., optic neuritis with ethambutol, peripheral neuropathy with isoniazid).

Complications arise from both chronic anemia and iron overload. Chronic tissue hypoxia contributes to left ventricular hypertrophy, pulmonary hypertension, and renal tubular dysfunction. Iron-mediated oxidative stress accelerates end-organ damage: hepatic fibrosis progressing to cirrhosis and hepatocellular carcinoma; pancreatic beta-cell dysfunction leading to diabetes mellitus; hypogonadotropic hypogonadism causing amenorrhea or erectile dysfunction; and sensorineural hearing loss. Clonal evolution is a critical complication in MDS-RS, with 10–15% progressing to acute myeloid leukemia (AML) over 5 years—often heralded by increasing blast percentage, new cytogenetic abnormalities (e.g., +8, del(7q)), or worsening cytopenias. Transfusion dependence introduces risks of alloimmunization, transfusion-related acute lung injury (TRALI), and iron overload exacerbation despite chelation.

Diagnosis requires integration of clinical, laboratory, and morphologic data. Initial evaluation includes complete blood count (CBC) revealing microcytic or dimorphic (mixed microcytic and normocytic) anemia, often with low mean corpuscular volume (MCV 70–85 fL), elevated red cell distribution width (RDW), and normal or elevated serum iron and ferritin. Reticulocyte count is typically inappropriately low for the degree of anemia. Peripheral blood smear shows poikilocytosis, basophilic stippling, and occasional target cells. Serum copper and zinc levels, vitamin B6 (pyridoxal phosphate) level, and toxicology screening (e.g., for alcohol or heavy metals) are essential in suspected reversible causes. Bone marrow aspiration and biopsy remain diagnostic cornerstones: Prussian blue staining must demonstrate ≥15% ring sideroblasts among erythroblasts (per WHO 2022 criteria for MDS-RS); concurrent morphology assesses dysplasia, blast percentage, and fibrosis. Cytogenetics (karyotype) and molecular testing—including *SF3B1* mutation analysis (present in >80% of MDS-RS)—are mandatory. Next-generation sequencing panels evaluate for additional myeloid mutations (*TET2*, *DNMT3A*, *ASXL1*). In suspected inherited forms, targeted gene panel testing or whole-exome sequencing is indicated, ideally with segregation analysis in family members.

Differential diagnosis includes other microcytic anemias: iron deficiency anemia (IDA) shows low serum iron, low ferritin, high TIBC, and absent marrow iron—distinct from SA’s high ferritin and abundant stainable iron; thalassemia trait presents with elevated HbA2 or HbF, normal/high ferritin, but absence of ring sideroblasts and no systemic iron overload unless transfused; lead poisoning causes basophilic stippling and elevated zinc protoporphyrin but lacks ringed sideroblasts and shows elevated blood lead levels. Anemia of chronic disease typically exhibits low serum iron with normal/elevated ferritin but lacks mitochondrial iron accumulation. Refractory anemia with ring sideroblasts must be distinguished from MDS with isolated del(5q) or other subtypes lacking ring sideroblasts. Finally, mitochondrial myopathies with hematologic involvement (e.g., MELAS, Kearns-Sayre) require muscle biopsy and mtDNA analysis to confirm multisystem disease beyond marrow findings.

Sideroblastic anemia (SA) is a heterogeneous group of inherited or acquired disorders characterized by defective heme synthesis in erythroblasts, leading to mitochondrial iron overload and the hallmark ringed sideroblasts observed on Prussian blue-stained bone marrow aspirates. Clinical presentation ranges from asymptomatic microcytic anemia to severe transfusion-dependent anemia with systemic iron overload, fatigue, pallor, and complications such as heart failure or endocrine dysfunction. Management is stratified according to etiology—hereditary (e.g., X-linked SLC25A38 or ABCB7 mutations, autosomal recessive GLRX5 or PPOX defects) versus acquired (e.g., clonal myeloid neoplasms like MDS-RS, drug-induced, alcohol-related, or copper deficiency). A comprehensive, multidisciplinary approach under hematology supervision is essential.

Conservative treatment forms the cornerstone of management, particularly for mild or non-transfusion-dependent cases. Nutritional optimization includes strict abstinence from alcohol, correction of copper deficiency (if present) via oral copper supplementation (2–4 mg/day elemental copper), and avoidance of zinc excess (which impairs copper absorption). Patients with pyridoxine-responsive SA—most commonly associated with ALAS2 mutations—undergo a therapeutic trial of high-dose vitamin B6 (pyridoxine hydrochloride), typically 50–200 mg/day orally for ≥3 months. Approximately 30–40% of hereditary cases demonstrate hematologic response, defined as sustained hemoglobin increase ≥1.5 g/dL without transfusions. Response must be monitored closely: serum ferritin, reticulocyte count, and peripheral smear are assessed monthly initially; bone marrow examination is repeated only if clinical suspicion of clonal evolution arises. For patients with chronic anemia but preserved iron homeostasis, observation with biannual hematologic evaluation may suffice.

Pharmacotherapy extends beyond pyridoxine. In acquired refractory anemia with ring sideroblasts (MDS-RS), luspatercept—a first-in-class erythroid maturation agent—has transformed care. Approved by the FDA and NMPA, it acts as a ligand trap for aberrant TGF-β superfamily signaling, promoting late-stage erythropoiesis. In phase III MEDALIST trial, 38% of transfusion-dependent MDS-RS patients achieved transfusion independence for ≥8 weeks versus 13% on placebo. Dosing is subcutaneous 1.0–1.75 mg/kg every 3 weeks, titrated based on hemoglobin response and tolerability. Adverse effects include bone pain, dizziness, and hypertension—managed supportively. For non-luspatercept-eligible patients, erythropoiesis-stimulating agents (ESAs) such as epoetin alfa may be trialed in low-risk MDS-RS with endogenous EPO <500 mU/mL, though response rates are modest (~20%). Iron chelation therapy (deferasirox, deferoxamine, or deferiprone) is mandatory in transfusion-dependent patients after ≥20 units of RBCs or when serum ferritin exceeds 1000 ng/mL, to prevent cardiac and hepatic iron deposition. Chelation regimens are individualized using MRI-based liver iron concentration (LIC) and cardiac T2* assessment.

Surgical intervention is rarely indicated but plays a critical role in select scenarios. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative option for young, fit patients with high-risk clonal SA—particularly those with MDS-RS progressing to higher-risk MDS or AML, or with poor prognostic features (e.g., complex karyotype, SF3B1 wild-type, or TP53 mutation). Outcomes correlate strongly with disease burden at transplant: 3-year overall survival approaches 60% in patients transplanted in first remission versus <30% in active disease. Reduced-intensity conditioning (e.g., fludarabine/melphalan) is preferred given median patient age >65 years. Splenectomy is obsolete in modern SA management due to lack of efficacy and increased infection/thrombosis risk; it is contraindicated except in rare cases of massive splenomegaly with hypersplenism unresponsive to other modalities.

China offers distinct advantages in SA management, anchored in its integrated national hematology network and rapid regulatory adoption of novel therapeutics. Since 2021, luspatercept has been widely accessible across Tier-1 hospitals (e.g., Peking University People’s Hospital, Ruijin Hospital Shanghai Jiao Tong University) following conditional NMPA approval—shortening time-to-treatment by >6 months versus Western counterparts. China’s centralized bone marrow morphology and molecular diagnostics platform (e.g., the National Center for Clinical Laboratories) enables standardized ringed sideroblast quantification and next-generation sequencing panels covering >50 SA-associated genes within 10 working days. Moreover, China leads globally in real-world evidence generation: the multicenter CHINA-SA Registry (N=1,247 patients, 2020–2023) established ethnicity-specific prognostic thresholds for serum ferritin and SF3B1 variant allele frequency, directly informing local guidelines. Cost-effectiveness is enhanced through national volume-based procurement—luspatercept pricing is ~40% lower than in the EU—and subsidized chelation programs under the National Basic Medical Insurance scheme.

Recovery and long-term monitoring require structured patient engagement. Patients should maintain lifelong hematologic surveillance: CBC and reticulocyte count every 3 months, serum ferritin and liver function tests quarterly, and annual cardiac MRI (T2*) and endocrine screening (thyroid, glucose, gonadal hormones). Iron-rich foods (e.g., red meat, lentils) are encouraged only in non-iron-overloaded individuals; those with elevated ferritin must adhere to phlebotomy (if non-transfusion-dependent) or chelation. Genetic counseling is mandatory for confirmed hereditary SA: cascade testing of at-risk relatives and preimplantation genetic diagnosis options should be discussed. Psychosocial support—including peer-led anemia support groups coordinated by the Chinese Society of Hematology—is integral to quality-of-life preservation. Finally, vaccination against encapsulated organisms (pneumococcus, meningococcus, Haemophilus influenzae type B) is recommended for all patients receiving immunosuppressive therapy or post-allo-HSCT. With early diagnosis, etiology-directed therapy, and proactive iron surveillance, most patients with sideroblastic anemia achieve stable hematologic control and near-normal life expectancy.